MAPK3 and glioblastoma: Taken together, these results suggest that in glioblastoma cells with normal DNA-PK activity, MYT1L may serve as an oncogene that contributes to the progression of glioblastoma by activating ERK1/2 and AKT signaling pathways, inhibiting apoptosis and shortening S phase in the cell cycle.